Ispecimen INC S-1 registration statements

iSpecimen Inc. has entered into a consulting agreement with IR Agency LLC and is proceeding with a public offering of its common stock.

iSpecimen Inc. has filed an S-1/A amendment detailing the terms of a proposed offering of common stock and pre-funded warrants.

iSpecimen Inc. has filed a registration statement for a best-efforts offering of up to $4 million in common stock and pre-funded warrants.

iSpecimen Inc. filed an S-1/A to register 1,559,828 shares for resale by selling stockholders, while also detailing its new $200 million Solana blockchain-based corporate treasury reserve initiative and ongoing Nasdaq compliance challenges.

iSpecimen Inc. filed an amended S-1 registration statement, revealing continued net losses, a new Solana-based corporate treasury initiative, and a resale offering of 1.56 million shares by selling stockholders.

iSpecimen Inc. reported a significant revenue decline and continued losses, raising substantial doubt about its ability to continue as a going concern, while also announcing plans for a high-risk Solana blockchain-based corporate treasury.

iSpecimen Inc. reports a significant 66% revenue drop and continued net losses for the first half of 2025, raising substantial doubt about its ability to continue as a going concern, despite recent capital raises.

iSpecimen, Inc. reports significant revenue decline and ongoing losses, raising substantial doubt about its ability to continue as a going concern, despite recent capital raises and cost-cutting measures.

iSpecimen Inc. is offering up to 4,040,404 shares of common stock and pre-funded warrants at $0.99 per share to raise approximately $3.5 million for marketing, technology acquisition, and working capital, despite a going concern warning from its auditors.

iSpecimen Inc. has filed an amended S-1 registration statement for a public offering of up to $4 million in common stock and pre-funded warrants, aiming to secure capital for marketing, technology acquisition, and general corporate purposes, amidst a 'going concern' warning from its auditors.

iSpecimen Inc. has filed an S-1/A amendment for an underwritten public offering of up to $4 million in common stock and pre-funded warrants, with auditors expressing substantial doubt about the company's ability to continue as a going concern.

iSpecimen Inc. is launching an underwritten public offering of up to $4 million in common stock and pre-funded warrants to fund marketing and technology development, as its auditor raises substantial doubt about the company's ability to continue as a going concern.

iSpecimen aims to raise $3 million through a public offering of common stock and pre-funded warrants to fund marketing, technology acquisition, and general corporate purposes.

iSpecimen Inc. seeks to raise up to $5 million through a best-efforts offering of common stock and pre-funded warrants to bolster its marketplace platform and address financial obligations.